Brexit: MHRA Grilling Gives A Regulator's View Of The Stakes
This article was originally published in SRA
Many of those in the life sciences sector who would be affected by a possible UK departure from the EU, including industry, scientists, the academic community and lawyers, have been happy to make their views known as to the likely effects. The voice of the drug regulators in this debate, though, has been understandably muted.
Register for our free email digests: